Executive Decisions Roundup
This article was originally published in The Tan Sheet
Executive Summary
ORA strategic deputy sought, CHPA names Brian Green CFO and Alternaturals’ leadership shake up continues.
You may also be interested in...
HBW Market News: CHPA CFO Awarded, Olive Natural Packaging, ODS Plan, IFF South America
CHAP’s Brian Green is Association TRENDS 2022 Association CFO of the Year; “Matisse-like dreamscape” In Olive Natural Packaging redesign; NIH’s ODS wants strategic plan input; and IFF innovation centers in Brazil, Chile, Colombia.
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.